Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07786142

Transition of Care in Pediatric Rare Endocrine Disorders

This study will evaluate the transition from pediatric to adult care in patients with pediatric-onset rare endocrine disorders. The study includes three components: a review of medical records to assess previous transition outcomes, a survey of adult patients about transition experiences and quality of life, and an evaluation of a structured transition program for participants aged 18 years or older. The transition program provides assessment of transition readiness, individualized education, clinical information transfer, coordinated care between pediatric and adult endocrinology teams, and follow-up after transfer. Researchers will evaluate transfer and retention in adult care, transition readiness, quality of life, appointment attendance, satisfaction, and clinical outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Daegu Catholic University Medical Center, Daegu, South Korea

Loading trial locations.

About this study

This study consists of three components. First, current transition practices and outcomes will be evaluated through retrospective medical record review. Second, a survey of adult patients will assess their transition experiences, unmet needs, and quality of life. Third, a standardized transition program will be prospectively evaluated in eligible participants preparing to transfer from pediatric to adult endocrinology care.

The transition program includes standardized assessment of transition readiness, disease knowledge, quality of life, and psychological status, together with individualized education, preparation of a clinical information summary and disease-specific checklist, coordinated transfer between pediatric and adult endocrinology teams, and follow-up after transfer.

The study is designed to characterize current transition practices and unmet needs and to evaluate whether a standardized transition program can improve the transition from pediatric to adult endocrine care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Diagnosis of a pediatric-onset rare endocrine disorder, including rare metabolic bone and mineral disorders, hypopituitarism, congenital adrenal hyperplasia, rare endocrine tumors, and syndromic or chromosomal disorders requiring endocrine care.
  • Currently receiving follow-up care in the pediatric endocrinology department of a participating institution.
  • Willing to participate in the standardized transition-of-care program and able to provide written informed consent.

Exclusion criteria

  • none

Treatment and study plan

Structured Transition-of-Care Program

Behavioral

The program includes assessment of transition readiness and disease knowledge, individualized education, preparation of a clinical information summary and disease-specific checklist, coordinated transfer between pediatric and adult endocrinology teams, and structured follow-up after transfer.

Primary outcomes

  1. Proportion of Participants Successfully Transferred to Adult Endocrinology Care

    Time frame: Within 6 months after transfer to adult endocrinology care

    The proportion of participants who successfully transfer to adult endocrinology care will be calculated as the number of participants who complete their first adult endocrinology outpatient visit after transfer from pediatric care divided by the number of participants enrolled in the standardized transition-of-care program.

Secondary outcomes

  1. Change in Transition Readiness Assessment Questionnaire Score

    Time frame: Baseline and at the first or second adult endocrinology visit after transfer

    Transition readiness will be assessed using the Transition Readiness Assessment Questionnaire at baseline and after transition to adult care. Scores will be calculated according to the validated scoring method, with higher scores indicating greater transition readiness. Change will be calculated as the post-transition score minus the baseline score.

  2. Change in Transition-Related Anxiety Score

    Time frame: Baseline and at the first or second adult endocrinology visit after transfer

    Transition-related anxiety will be assessed at baseline and after transition to adult care using the study-specific transition evaluation questionnaire. Change will be calculated as the post-transition score minus the baseline score, with higher scores indicating greater transition-related anxiety.

  3. Participant Satisfaction With the Transition Process

    Time frame: Baseline and at the first or second adult endocrinology visit after transfer

    Participant satisfaction with the transition program and adult-oriented care will be assessed using the post-transition evaluation questionnaire. The total score will be calculated according to the study-specific scoring method, with higher scores indicating greater satisfaction.

  4. Retention in Adult Endocrinology Care at 12 Months

    Time frame: 12 months after the first adult endocrinology visi

    The proportion of participants who remain in adult endocrinology care at 12 months after their first adult endocrinology visit will be assessed. Retention will be defined as continued attendance at scheduled adult endocrinology follow-up visits during the 12-month period.

Study contacts

Contact information is provided by the study sponsor or research team.

Yun Jeong Lee

CONTACT

[email protected]

82-2-2072-2811

Yunsoo Choe

CONTACT

[email protected]

82-2-2072-5323

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • SNUH Lee Kun-hee Child Cancer & Rare Disease Project

Registry information

Official study title

Transition of Care in Pediatric Rare Endocrine Disorders: Assessing Unmet Needs and Implementing a Standardized Transition Program

Acronym: TRANSPIRE

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 25, 2026
Registry last updated
Aug 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.